A Philadelphia jury ordered Tuesday
Johnson & Johnson
to pay $ 8 billion in damages to a Maryland man who said his use of J & J's antipsychotic Risperdal as a child caused enlarged breasts and the company failed to warn of this risk in the right way.
the largest award so far among more than 13,000 lawsuits against J&J alleging that Risperdal caused a condition called gynecomastia in boys, which involves breast tissue enlargement. The lawsuits generally claim that J&J was aware of the risk of this side effect, but underestimated the risk of doctors.
It is also the latest in a series of costly legal setbacks for J&J in a series of lawsuits alleging product and other claims. In August, a Oklahoma judge ordered the company to pay $ 572 million to have contributed to the state's opioid addiction crisis.
Last year, a St. Louis jury found J&J to pay $ 4.69 billion in damages to 22 women and their families who caused ovarian cancer cases using the company's baby powder.
J&J has denied the allegations and seeks to appeal the baby powder and opioid decisions. Last week, J&J said it agreed to pay $ 20.4 million to settle lawsuits filed by two Ohio counties that allege the company helped raise the opioid epidemic; the company did not admit liability.
When deciding an appeal, judges often reduce punitive damages rates from juries.
The last verdict stems from a case brought by
who said that the use of Risperdal between 2003 and 2008 caused gynecomastia. In 201
A court of appeal later overturned the judge's decision on punitive damages, and cleared the way for the criminal case phase of the trial starting in September, which ends with Tuesday's verdict.
J&J, based in New Brunswick, NJ, said in a statement Tuesday that it will immediately move "to set this aside excessive and unfounded judgment. "The company said the amount was" grossly disproportionate "to the original $ 680,000 compensatory award, and it is certain the verdict will be reversed.
J&J said it was barred from presenting meaningful defense because of the court's exclusion of key evidence, and the Risperdal prescriptive label outlining its risks.
Mr. Murray's attorneys, Thomas Kline and
said in a statement that the jury "astoundingly told Johnson & Johnson that the actions were deliberate and malicious." patent exclusivity in 2008.
Write to Peter Loftus at firstname.lastname@example.org
Copyright © 2019 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8